Home
Elisabet Ognedal Berge's picture

Elisabet Ognedal Berge

Researcher
  • E-mailElisabet.Berge@uib.no
  • Phone+47 55 97 64 47
  • Visitor Address
    Haukeland universitetssykehus, Laboratoriebygget
  • Postal Address
    Postboks 7804
    5020 Bergen
Journal articles
  • Lønning, Per Eystein; Berge, Elisabet Ognedal; Bjørnslett, Merete Pauline; Minsaas, Laura; Chrisanthar, Ranjan; Vetti, Hildegunn Høberg; Dulary, Cécile; Busato, Florence; Bjørneklett, Silje; Eriksen, Christine; Kopperud, Reidun Kristin; Axcrona, Ulrika; Davidson, Ben; Bjørge, Line; Evans, D. Gareth; Howell, Anthony; Salvesen, Helga; Janszky, Imre; Hveem, Kristian; Romundstad, Pål Richard; Vatten, Lars Johan; Tost, Jörg; Dørum, Anne; Knappskog, Stian. 2018. White blood cell BRCA1 promoter methylation status and ovarian cancer risk. Annals of Internal Medicine. 168: 326-334. doi: 10.7326/M17-0101
  • Knappskog, Stian; Berge, Elisabet Ognedal; Chrisanthar, Ranjan; Geisler, Stephanie; Staalesen, Vidar; Leirvaag, Beryl; Yndestad, Synnøve; de Faveri, Elise Norheim; Karlsen, Bård Ove; Wedge, David C.; Akslen, Lars A.; Lilleng, Peer Kåre; Løkkevik, Erik; Lundgren, Steinar; Østenstad, Bjørn; Risberg, Terje; Mjaaland, Ingvil; Aas, Turid; Lønning, Per Eystein. 2015. Concomitant inactivation of the p53- and pRB- functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo. Molecular Oncology. 9: 1553-1564. doi: 10.1016/j.molonc.2015.04.008
  • Berge, Elisabet Ognedal; Huun, Johanna; Lillehaug, Johan R.; Lønning, Per Eystein; Knappskog, Stian. 2013. Functional characterisation of p53 mutants identified in breast cancers with suboptimal responses to anthracyclines or mitomycin. Biochimica et Biophysica Acta - General Subjects. 1830: 2790-2797. doi: 10.1016/j.bbagen.2012.12.004
  • Birkeland, Einar Elvbakken; Busch, Christian; Berge, Elisabet Ognedal; Geisler, Jürgen; Jonsson, Göran; Lillehaug, Johan R.; Knappskog, Stian; Lønning, Per Eystein. 2013. Low BRAF and NRAS expression levels are associated with clinical benefit from DTIC therapy and prognosis in metastatic melanoma. Clinical and Experimental Metastasis. 30: 867-876. doi: 10.1007/s10585-013-9587-4
  • Berge, Elisabet Ognedal; Knappskog, Stian; Lillehaug, Johan R.; Lønning, Per Eystein. 2011. Alterations of the retinoblastoma gene in metastatic breast cancer. Clinical and Experimental Metastasis. 28: 319-326. doi: 10.1007/s10585-011-9375-y
  • Berge, Elisabet Ognedal; Knappskog, Stian; Geisler, Stephanie; Staalesen, Vidar; Pacal, Marec; Børresen-Dale, Anne-Lise; Puntervoll, Pål; Lillehaug, Johan R.; Lønning, Per Eystein. 2010. Identification and characterization of retinoblastoma gene mutations disturbing apoptosis in human breast cancers. Molecular Cancer. 9. 13 pages. doi: 10.1186/1476-4598-9-173
  • Berge, Elisabet Ognedal; Staalesen, Vidar; Straume, Anne Hege; Lillehaug, Johan R.; Lønning, Per Eystein. 2010. Chk2 splice variants express a dominant-negative effect on the wild-type Chk2 kinase activity. BBA - Molecular Cell Research. 1803: 386-395. doi: 10.1016/j.bbamcr.2010.01.005
  • Bruins, Slot Karsten Mark Herman; Berge, Eivind. 2009. Thrombolytic Treatment for Stroke: Patient Preferences for Treatment, Information, and Involvement. Journal of Stroke & Cerebrovascular Diseases. 18: 17-22. doi: 10.1016/j.jstrokecerebrovasdis.2008.06.009
  • Bruins, Slot Karsten Mark Herman; Berge, Eivind; Dorman, Paul; Lewis, Steff; Dennis, Martin; Sandercock, Peter. 2008. Impact of functional status at six months on long term survival in patients with ischaemic stroke: prospective cohort studies. BMJ. British Medical Journal.
  • Chrisanthar, Ranjan; Knappskog, Stian; Løkkevik, Erik; Anker, Gun Birgitta; Østenstad, Bjørn; Lundgren, Steinar; Berge, Elisabet Ognedal; Risberg, Terje; Mjaaland, Ingvil; Mæhle, Lovise Olaug; Engebretsen, Lars Fredri; Lillehaug, Johan; Lønning, Per Eystein. 2008. CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer. PLOS ONE. 3:e0003062. 15 pages. doi: 10.1371/journal.pone.0003062
  • Berge, Eivind; Foss, Kari Bente; Sandset, Else Charlotte; Haugbro, Kaia Kristine; Turkovic, Meliha; Sandset, Per Morten. 2007. The Factor V Leiden, Prothrombin Gene 20210GA, Methylenetetrahydrofolate Reductase 677CT and Platelet Glycoprotein IIIa 1565TC Mutations in Patients With Acute Ischemic Stroke and Atrial Fibrillation. Stroke. 38: 1069-1071. Published 2007-02-08. doi: 10.1161/01.STR.0000258076.04860.8e
  • Russell, David; Thomassen, Lars; Indredavik, Bent; Sandset, Per Morten; Joakimsen, Oddmund; Berge, Eivind. 2004. Pasienter med akutt hjerneinfarkt bør få trombolytisk behandling. Tidsskrift for Den norske legeforening. 124: 1666-1667.
  • Berge, Eivind; Abdelnoor, Michel; Nakstad, Per Hjalmar; Sandset, Per Morten. 2000. Heparin in acute embolic stroke trial (HAEST) - A double-blind, randomised study on the effect of low molecular weight heparin and aspirin in patients with acute ischaemic stroke and atrial fibrillation. The Lancet. 355: 1205-1210.
  • Berge, Eivind; Sandset, Per Morten. 2000. Heparin versus aspirin in ischaemic stroke. The Lancet. 356: 504-504.
  • Berge, Eivind; Sandset, Per Morten. 1996. Hva er den beste behandlingen ved kardioembolisk hjerneslag? Tidsskrift for Den norske legeforening. 116: 97-97.
  • Sandset, Per Morten; Berge, Eivind. 1996. Emboliske komplikasjoner ved atrieflimmer. Nytt om legemidler forts. av: Nytt fra Statens legemiddelkontroll. 11: 15-16.

More information in national current research information system (CRIStin)